01—Abstract
Summary
Summary of the 10-K filed February 12, 2025. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 2024 10-K filing highlights a year of robust growth and strategic acquisitions, underscoring its position as a global leader in medical technologies.
The company reported a 10.2% increase in net sales, reaching $22.595 billiona, driven by strong performance across both its MedSurg and Neurotechnology (up 11.1%) and Orthopaedics (up 8.9%) segments. This growth was fueled by increased unit volumes and, to a lesser extent, higher pricing, demonstrating resilience in a dynamic healthcare market. The company also completed several strategic acquisitions totaling $1.628 billion, further expanding its product portfolios and market reach.
Financially, Stryker maintained healthy profitability with a gross profit margin of 63.9%. However, net earnings saw a slight decrease to $2.993 billionb from $3.165 billion in the prior year, partly due to significant goodwill impairments related to its Spine business, amounting to $456 million, and a $362 million loss recognized on assets held for sale within the Spinal Implants business.
Despite these charges, operating income remained strong. The company continued its commitment to capital allocation, investing in acquisitions, paying $1.219 billionc in dividends, and maintaining a strong liquidity position with $3.743 billion in cash, cash equivalents, and marketable securities.
02—Key points
Key Highlights
- Stryker reported a 10.2% year-over-year increase in net sales, reaching $22.595 billion, indicating strong market demand and execution.
- Both major segments, MedSurg and Neurotechnology (11.1% growth) and Orthopaedics (8.9% growth), contributed to the top-line expansion.
- The company made significant strategic investments in acquisitions, totaling $1.628 billion, aimed at enhancing its product offerings and market presence.
- Despite overall sales growth, net earnings decreased to $2.993 billion due to substantial goodwill impairments ($456 million) and a loss on assets held for sale ($362 million) within the Spine business.
- Gross profit margin remained robust at 63.9%, demonstrating effective cost management and pricing power.
- Stryker maintained a strong financial position with $3.743 billion in cash, cash equivalents, and marketable securities and a commitment to returning capital to shareholders through dividends ($1.219 billion paid).
- The company is actively managing its product portfolio, evidenced by the reclassification and planned sale of its US Spinal Implants business.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Stryker Corp kept $0.13.
- Revenue$22.59B100.0%
- Cost of revenue−$8.15B36.1%
- Gross profit$14.44B63.9%
- Operating costs−$10.75B47.6%
- Operating income$3.69B16.3%
- Interest, other & tax−$696.0M3.1%
- Net income$2.99B13.2%
Where FY2024 revenue went
$22.59B- Cost of revenue: $8.15B, 36% of revenue
- SG&A: $7.68B, 34% of revenue
- Net income: $2.99B, 13% of revenue
- R&D: $1.47B, 6.5% of revenue
- Other operating costs: $1.60B, 7.1% of revenue
- Interest, other & tax: $696.0M, 3.1% of revenue
Kept 13% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 12, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $22.59B$20.50B | +10.2% |
| Cost of Revenue | $8.15B$7.44B | +9.6% |
| Gross Profit | $14.44B$13.06B | +10.6% |
| R&D Expenses | $1.47B$1.39B | +5.6% |
| SG&A Expenses | $7.68B$7.11B | +8.1% |
| Operating Expenses | $10.75B$9.17B | +17.2% |
| Operating Income | $3.69B$3.89B | −5.1% |
| Interest Expense | $396.00M$356.00M | +11.2% |
| Net Income | $2.99B$3.17B | −5.4% |
| EPS (Basic) | $7.86$8.34 | −5.8% |
| EPS (Diluted) | $7.76$8.25 | −5.9% |
| Shares Outstanding (Basic) | 381.00M379.60M | +0.4% |
| Shares Outstanding (Diluted) | 385.60M383.70M | +0.5% |
05—Questions
Frequently Asked Questions
What was Stryker's overall financial performance in 2024?
Stryker reported a 10.2% increase in net sales, reaching $22.595 billion. While gross profit increased by 10.6%, net earnings decreased by 5.4% to $2.993 billion, primarily due to significant goodwill impairments related to its Spine business and a loss on assets held for sale within the Spinal Implants business. Adjusted net earnings per diluted share grew by 15.0% to $12.19.
How did Stryker's business segments perform?
The MedSurg and Neurotechnology segment saw net sales increase by 11.1% to $13.518 billion, while the Orthopaedics segment's net sales grew by 8.9% to $9.077 billion. Both segments benefited from increased unit volumes and higher prices.
What significant strategic moves did Stryker make in 2024?
Stryker completed several acquisitions totaling $1.628 billion, aimed at strengthening its product portfolios in areas like Instruments, Endoscopy, Medical, Neuro Cranial, Trauma and Extremities, and Joint Replacement. Additionally, the company committed to selling certain assets within its Spinal Implants business and entered into an agreement to acquire Inari Medical, Inc. for approximately $4.9 billion.
What are the main risks and challenges highlighted in the filing?
Key risks include supply chain disruptions, inflationary pressures, pricing pressures from cost containment measures, intense competition, regulatory compliance (particularly the EU MDR), cybersecurity threats, integration risks from acquisitions, and potential impacts from geopolitical events and climate change. The company also noted goodwill impairments related to its Spine business as a significant event impacting its financial results.
06—Continue